PRESS RELEASE published on 11/04/2025 at 07:30, 6 months 19 days ago Informations privilégiées / Communiqué sur comptes, résultats MaaT Pharma annonce ses activités de financement et résultats financiers T3 2025, incluant un accord avec Clinigen augmentant le CA de 45% Résultats Financiers Croissance Financement MaaT Pharma Accord Clinigen
BRIEF published on 10/13/2025 at 14:52, 7 months 10 days ago Franchissement de Seuils par Invus Public Equities dans MAAT PHARMA Droits De Vote Franchissement De Seuils Cession D'actions MaaT Pharma Invus Public Equities
BRIEF published on 10/13/2025 at 14:52, 7 months 10 days ago Crossing of Thresholds by Invus Public Equities in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Invus Public Equities
PRESS RELEASE published on 10/13/2025 at 14:47, 7 months 10 days ago Franchissement de seuils Déclaration de franchissement de seuils par Invus Public Equities pour MAAT PHARMA avec 4,96% du capital et des droits de vote suite à une cession d'actions sur le marché Franchissement De Seuils Marché Cession D'actions MaaT Pharma Invus Public Equities
PRESS RELEASE published on 10/07/2025 at 07:30, 7 months 16 days ago Informations privilégiées / Autres communiqués
BRIEF published on 10/06/2025 at 14:59, 7 months 17 days ago Symbiosis LLC réduit sa participation dans MAAT PHARMA Droits De Vote Franchissement De Seuils Cession D'actions MaaT Pharma Symbiosis LLC
BRIEF published on 10/06/2025 at 14:59, 7 months 17 days ago Symbiosis LLC Reduces Stake in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Symbiosis LLC
PRESS RELEASE published on 10/06/2025 at 14:54, 7 months 17 days ago Franchissements de seuils Déclarations de franchissements de seuils par Symbiosis LLC1 concernant MAAT PHARMA publiées par l'AMF le 3 octobre 2025 AMF Franchissements De Seuils MaaT Pharma Régularisation Symbiosis LLC1
BRIEF published on 09/17/2025 at 07:35, 8 months 6 days ago MaaT Pharma dévoile ses résultats semestriels 2025 Résultats Semestriels MaaT013 Efficacité Accord Clinigen Financement BEI Croissance Revenus
BRIEF published on 09/17/2025 at 07:35, 8 months 6 days ago MaaT Pharma unveils its 2025 half-year results Revenue Growth Half-year Results EIB Financing MaaT013 Efficiency Clinigen Agreement
Published on 05/23/2026 at 19:45, 9 hours 22 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 1 hour ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 2 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 2 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 2 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 16:30, 12 hours 37 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 13 hours 10 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 9 hours ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 19:35, 1 day 9 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
